IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

In Process And Finished Product Quality Control Tests For Sterile And Non-Sterile Dosage Form.

[1]Sachin S.Sapkal, [2]Tejashree R.Kedar, [3]Prasad B. Tanpure, [4]Sagar R. Kale, [5]Sadiya S.Inamdar

[1]Student, [2]Professor, [3]Student, [4]Student, [5]Student

Arihant College of Pharmacy, Kedgaon, Ahilyanagar, Maharashtra, India, 414005.

Abstract :

This review article presents a comprehensive overview of the in-process and finished product quality control tests essential for ensuring the safety, efficacy, and quality of both sterile and non-sterile dosage forms within the pharmaceutical industry. The article delves into the critical role of quality control in safeguarding public health and maintaining regulatory compliance.

A detailed examination of In-process quality control (IPQC) is provided, encompassing tests for raw materials, intermediate products, and in-process materials. The article highlights the importance of IPQC in identifying and rectifying potential issues early in the manufacturing process, thereby minimizing risks and ensuring product integrity.

Furthermore, the review explores finished product quality control (FPQC), focusing on the comprehensive testing of final products to verify their adherence to established specifications. Key FPQC tests, including identity, assay, purity, physical properties, chemical stability, bioavailability, sterility, pyrogen, particulate matter, and package integrity testing, are discussed in detail.

The article specifically addresses the unique quality control requirements for sterile and non-sterile dosage forms. For sterile products, such as injections and ophthalmic solutions, the importance of sterility testing, pyrogen testing, particulate matter testing, and package integrity testing is emphasized. In contrast, non-sterile dosage forms, including tablets and capsules, require rigorous evaluation of dissolution, disintegration, uniformity of dosage units, and content uniformity.

Keywords: Quality control , Pharmaceutical manufacturing, Sterile dosage forms,Non-sterile dosage forms.

1)Introduction:

Quality control (QC) is a critical aspect of pharmaceutical manufacturing, ensuring that products meet established standards of safety, efficacy, and purity. This review article focuses on the in-process and finished product QC tests for both sterile and non-sterile dosage forms.

Key points:

1) Importance of QC: QC is essential for protecting public health and ensuring regulatory compliance.

2)In-process QC: Involves testing raw materials, intermediate products, and in-process materials at various stages of manufacturing.

3)Finished product QC: Ensures that the final product meets all specified quality attributes before release.

4) Sterile and non-sterile dosage forms: Each type has unique quality requirements.

5)Regulatory compliance: QC must adhere to industry standards and regulations.

By understanding the in-process and finished product QC tests for both sterile and non-sterile dosage forms, pharmaceutical manufacturers can ensure the safety, efficacy, and quality of their products.

2)Importance of Quality Control:

Quality control (QC) is a critical aspect of pharmaceutical manufacturing, ensuring that products meet established standards of safety, efficacy, and purity. It plays a pivotal role in protecting public health and maintaining regulatory compliance.

1)Safety: QC helps prevent the release of defective or contaminated products that could pose a risk to patients.

2) Efficacy: QC ensures that products deliver the intended therapeutic benefits.

3)Purity: QC safeguards products from impurities or contaminants that could compromise their quality.

4)Regulatory compliance: QC helps pharmaceutical manufacturers adhere to stringent industry standards and regulations.

5)Brand reputation: Consistent quality control contributes to a positive brand image and consumer trust.

6)Cost reduction: QC can help identify and prevent defects early in the manufacturing process, reducing waste and costs.

In summary, QC is essential for ensuring the safety, efficacy, and quality of pharmaceutical products, protecting public health, and maintaining regulatory compliance.

3)In-Process Quality Control (IPQC):

In-process quality control (IPQC) involves testing raw materials, intermediate products, and in-process materials at various stages of manufacturing to identify and correct potential issues early on. This proactive approach helps to minimize risks and ensure the quality of the final product.

Key aspects of IPQC:

1)Raw material testing: Verifying the identity, purity, and quality of raw materials before they are used in the manufacturing process.

2)Intermediate product testing: Assessing the quality of products at different stages of production to identify and address any issues early.

3)In-process testing: Monitoring the manufacturing process to ensure adherence to established procedures and specifications.

Common IPQC tests:

4)Identity tests: Confirming the presence of the correct active ingredient.

5)Assay tests: Determining the accurate quantity of the active ingredient.

6)Purity tests: Assessing the absence of impurities or contaminants.

7)Physical properties: Evaluating attributes like appearance, odor, and taste.

8)Microbial testing: Checking for the presence of microorganisms, especially in sterile products.

9)Environmental monitoring: Ensuring a clean and controlled manufacturing environment.

By implementing effective IPQC procedures, pharmaceutical manufacturers can identify and address potential quality issues early in the manufacturing process, reducing the risk of product recalls and ensuring the safety and efficacy of their products.

4)Finished Product Quality Control (FPQC):

Finished product quality control (FPQC) involves testing the final product to verify its compliance with established specifications. It is the final line of defense in ensuring the safety, efficacy, and quality of pharmaceutical products before they are released to the market.

Key aspects of FPQC:

1)Comprehensive testing: FPQC involves a wide range of tests to assess the product's quality attributes.

2)Regulatory compliance: FPQC must adhere to stringent regulatory requirements, such as those set by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

3)Documentation: Detailed documentation of FPQC activities is essential for traceability and compliance.

Common FPQC tests:

4)Identity, assay, and purity tests: Similar to IPQC, but on the finished product.

5)Physical properties: Including appearance, weight, and dissolution.

6)Chemical stability: Assessing the product's stability over time.

7)Bioavailability: Determining the rate and extent of drug absorption.

8)Sterility testing: For sterile products, confirming the absence of viable microorganisms.

9)Pyrogen testing: For parenteral products, ensuring the absence of pyrogens (fever-inducing substances).

10)Particulate matter testing: For parenteral and ophthalmic products, assessing the presence of visible particles.

11)Package integrity testing: Ensuring the integrity of the packaging.

By conducting thorough FPQC testing, pharmaceutical manufacturers can ensure that their products meet the highest quality standards and are safe for use.

Sterile and Non-Sterile Dosage Forms

Pharmaceutical dosage forms can be classified into two main categories: sterile and non-sterile.

5)Sterile Dosage Forms:

Sterile dosage forms are intended for parenteral administration, such as injections, or for direct application to the eye or other sterile body sites. They must be free from viable microorganisms to prevent infections.

Examples of sterile dosage forms:

1)Injections (e.g., intravenous, intramuscular, subcutaneous)

2)Ophthalmic solutions and suspensions

3)Topical creams and ointments for sterile wounds

4)Nasal sprays

Non-Sterile Dosage Forms

Non-sterile dosage forms are not intended for direct contact with sterile body sites. They may be administered orally, rectally, or topically to the skin. While they must still meet stringent quality standards, they do not require the same level of sterility as sterile products.

Examples :Tablets,Capsules, Syrups,Suspensions, Suppositories

It is important to note that even non-sterile dosage forms must be manufactured under hygienic conditions to prevent contamination with harmful microorganisms.

6)Regulatory Compliance in Pharmaceutical Manufacturing:

Pharmaceutical manufacturing is a highly regulated industry, with stringent requirements in place to ensure the safety, efficacy, and quality of products. Adherence to regulatory standards is essential for protecting public health and maintaining market access.

Key regulatory bodies:

1)Food and Drug Administration (FDA): The primary regulatory agency for pharmaceuticals in the United States.

2)European Medicines Agency (EMA): The primary regulatory agency for pharmaceuticals in the European Union.

3)National regulatory authorities: Each country has its own regulatory agency overseeing pharmaceutical manufacturing.

Regulatory requirements:

4)Good Manufacturing Practices (GMP): A set of guidelines that establish standards for the manufacture, testing, and control of pharmaceutical products.

5)Quality Management Systems (QMS): A systematic approach to managing quality throughout an organization.

6)Labeling and packaging requirements: Ensuring accurate and informative labeling and packaging.

7)Clinical trials: Conducting rigorous clinical trials to demonstrate safety and efficacy.

8)Adverse event reporting: Reporting adverse events associated with pharmaceutical products.

9)Recall procedures: Having procedures in place for recalling defective or contaminated products.

10)Public health protection: Ensures the safety and efficacy of pharmaceutical products.

11)Market access: Allows for the sale and distribution of products in different markets.

12)Brand reputation: Demonstrates commitment to quality and safety.

13)Reduced risk of legal issues: Adherence to regulations minimizes the risk of legal actions.

Conclusion:

In-process and finished product quality control tests are essential for ensuring the safety, efficacy, and quality of pharmaceutical products. By implementing rigorous QC procedures, manufacturers can minimize risks, maintain product integrity, and comply with regulatory requirements.QC is crucial for protecting public health and ensuring product safety.In-process and finished product testing: Both are essential for identifying and addressing quality issues. Adherence to regulatory standards is essential for market access and public health protection. Each type has unique quality requirements.By understanding the in-process and finished product QC tests for both sterile and non-sterile dosage forms, pharmaceutical manufacturers can ensure the safety, efficacy, and quality of their products, thereby contributing to the overall well-being of patients.

References :-

1) Japanese Pharmacopoeia. The Ministry of health, Labour And Welfare Ministerial Notification No. 14thed, 285, 2001,112-19.
2) Chaudhari PD, Chaudhari SP, Lanke SD, Patel N. Formulation and in vitro evaluation of taste maskedOrodispersible dosage form of Levocetirizine. Indian JPharm Educ Res. 41, 2007, 319-28.
3) Available at: http//Krishnakanth. B, In process Quality Control test for Tablets R.S Bhat, 2010, 2-9.
4) Leon L, Herbert AL, Joseph L. Kanig: The Theory and Practice of indust

5) Akash M, Priya darshani K, Rathor RPS, Abhilasha. A ReviewOn comparative study of in-process and finished products Quality Control tests for sterile and non-sterile dosageForm. Int J Institutional Phar Life Sci. 5(2), 2015, 52-65.
6) Atkers MJ, Larrimor DS, Guazzao MD. "Parenteral QualityControl" New York, Marcel Decker, 2006, 180-3.
7) British Pharmacopoeia. Published on behalf of Medicines And Health care products Regulatory Agency; The Department of Health, social services and public safety.Great Britain. Volume II, 6 Th ed. 2010, 6502-10.
8) Deshmukh MT, Salunkhe RS, Deshmukh VT, Shete RV. Quality Control Test's for Parenteral Preparations: A Review. J Current Pharm Res. 5(2), 2015, 1425-30.
9) Available at: www.yogipandya/ipqc-solid dosage forms: 2013.
10) Shirisha V, Somsubhra G, Rajni B, David B. An Updated Review on IPQC Tests for Sterile and Non Sterile Products. Research J. Pharm. And Tech. 7(2), 2014, 255-65.
11) Indian Pharmacopoeia. The Controller of publication, New Delhi; Ministry of Health and Family welfare. Volume I. India 5 Th ed. Particulate contamination. 2007, 28, 54, 182, 187, 188-90.
12) Srujana N, Nitin VC, Ravi V, Balamuralidhara V, Pramodkumar TM. Comparative study of In-Process and Finished product Quality control test's of BP, USP, EP, IP for Parenterals. Am. J. PharmTech Res. 2(3), 2012, 305-25.
13) European Pharmacopoeia. Prepared under Council of Europe and European Pharmacopoeial Commission, 5 Thed, 2005, 337-44.
14) Jayasree M, Sowmya C, Divya L, Niranjan MB, Rajasekhar VR, Lavakumar V. Injectable Preparations-An Emerging Dosage Forms. Int J Advanced Pharm. 4(1), 2014, 36-41.